Achillion gains on HCV data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) was up $0.81 (10%) to $9.25 on Friday after reporting interim data from a Phase II study of HCV compound ACH-3102. All 12 treatment-naïve patients with genotype 1 infection had a sustained virologic response four weeks (SVR4) after the end of treatment. Patients received once-daily 50 mg ACH-3102 plus 400 mg Sovaldi sofosbuvir for eight weeks.

Based on the interim data, Achillion said 12 additional patients will receive the combination once daily for six weeks. SVR4 data from additional patients are expected by year end. ...